Aspo Pharmaceuticals Llp Profile
Key Indicators
- Obligation of Contribution ₹ 2.00 Cr
as on 10-12-2024
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.63 Cr
as on 10-12-2024
- Revenue -73.70%
(FY 2021)
- Profit 53.20%
(FY 2021)
- Ebitda 84.40%
(FY 2021)
- Total Assets 40.90%
(FY 2021)
About Aspo Pharmaceuticals Llp
The LLP status is Active, and it has filed its Accounts and Solvency Statement up to 31 Mar 2023 (FY 2022-2023). It's Total Obligation of Contribution is Rs 2.00 Cr as per MCA.
- CIN/LLPIN/FCRN
AAL-1485
- Incorporation Date
15 Nov 2017
- Date of Accounts and Solvency Statement
31 Mar 2023
- ROC Code
Roc-Himachalpradesh
- Company Classification
Limited Liability Partnership
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aspo Pharmaceuticals Llp?
Designated Partners(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikas Gupta  | Designated Partner | 19-Jul-2018 | Current |
| Vivek Jindal | Designated Partner | 01-Jun-2021 | Current |
| Deepak Gupta | Designated Partner | 19-Jul-2018 | Current |
| Munish Gupta | Designated Partner | 19-Jul-2018 | Current |
| Sanchit Garg | Designated Partner | 19-Jul-2018 | Current |
| Arvind Jindal | Designated Partner | 01-Jun-2021 | Current |
Financial Performance of Aspo Pharmaceuticals Llp.
Aspo Pharmaceuticals Llp, for the financial year ended 2021, experienced significant reduction in revenue, with a 73.7% decrease. The company also saw a substantial improvement in profitability, with a 53.2% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aspo Pharmaceuticals Llp?
Unlock access to Aspo Pharmaceuticals Llp's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Aspo Healthcare Private LimitedActive 3 years 2 monthsDeepak Gupta and Munish Gupta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab National Bank Creation Date: 18 Jun 2022 | ₹8.10 M | Open |
Punjab National Bank Creation Date: 11 Nov 2021 | ₹0.57 M | Open |
Punjab National Bank Creation Date: 11 Nov 2021 | ₹4.10 M | Open |
How Many Employees Work at Aspo Pharmaceuticals Llp?
Aspo Pharmaceuticals Llp has a workforce of 83 employees as of Dec 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aspo Pharmaceuticals Llp, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aspo Pharmaceuticals Llp's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
